New angiotensin II type 1 receptor blocker olmesartan improves portal hypertension in patients with cirrhosis

Hepatology Research

Volumn 37, Issue 12, 2007, Pages 1011-1017

  Hidaka, Hisashi ^a   Kokubu, Shigehiro ^b   Nakazawa, Takahide ^a   Okuwaki, Yuusuke ^a   Ono, Kouji ^a   Watanabe, Masaaki ^a   Shibuya, Akitaka ^a   Saigenji, Katsunori ^a  

^a KITASATO UNIVERSITY HOSPITAL   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II type 1 receptor blocker; Endoscopicband ligation; Esophagealvariceal bleeding; Hepaticvenous pressure gradient; Non selective beta blocker; Portal hypertension

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; OLMESARTAN; PROTHROMBIN; SCLEROSING AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS VARICES BLEEDING; FEMALE; HEART RATE; HEMODYNAMIC PARAMETERS; HUMAN; KIDNEY FUNCTION TEST; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MALE; MEAN ARTERIAL PRESSURE; OUTCOME ASSESSMENT; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PORTAL VEIN BLOOD PRESSURE; PORTAL VEIN THROMBOSIS; PORTOSYSTEMIC ANASTOMOSIS; PRESSURE GRADIENT; PRIORITY JOURNAL; PROTHROMBIN TIME; SCLEROTHERAPY; TREATMENT DURATION; TREATMENT OUTCOME; VEIN LIGATION;

EID: 35648983411     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00165.x     Document Type: Article

References (19)

1. North Italian Endoscopic Club (NIEC) for the Study and Treatment of Esophageal Varices. Prevention of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter trial. N Engl J Med 1988; 319: 983-9.
2. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: An evidence-based approach. Semin Liver Dis 1999; 19: 475-505.
3. Schneider AW, Friedrich J, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999; 29: 334-9.
4. Gonzalez-Abraldes J, Albillos A, Banares R et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001; 121: 382-8.
5. Mizuno M, Sada T, Ikeda M et al. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 1995; 285: 181-8.
6. Oparil S, Williams D, Chrysant S, Marbury T, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3: 283-91.
7. Japanese Research Society for Portal Hypertension. The General Rules for Recording Endoscopic Findings of Esophageal Varices - revised edition. Acta Hepatol Jpn 1991; 33: 277-81. (In Japanese with English abstract.)
8. Feu F, Garcia-Pagan JC, Bosch J et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal heamorrhage in patients with cirrhosis. Lancet 1995; 346: 1056-9.
9. Bosch J, Mastai R, Kravetz D et al. Effects of propranolol on azygos blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology 1984; 4: 1200-5.
10. Garcia-Tsao G, Grace ND, Groszmann RJ et al. Short-term effects of propranolol on portal venous pressure. Hepatology 1986; 6: 101-6.
11. Vorobioff J, Picabea E, Villavicencio R et al. Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients. Hepatology 1987; 7: 648-53.
12. Lebrec D, Hillon P, Munoz C et al. The effect of propranolol on portal hypertension in patients with cirrhosis: A hemodynamic study. Hepatology 1982; 2: 523-7.
13. Groszmann RJ, Garcia-Tsao G, Bosch J et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005; 353: 2254-61.
14. Bataller R, Gines P, Nicolas JM et al. Angiotensin II-induced contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000; 118: 1149-56.
15. Rocky DC. The cellular pathogenesis of portal hypertension: Stellate cell contractility, endothelin and nitric oxide. Hepatology 1997; 25: 2-5.
16. Schepke M, Werner E, Biecker E et al. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology 2001; 121: 389-95.
17. Von Bergmann K, Laeis P, Puchler K, Sudhop T, Schwocho L, Gonzalez T. Olmesartan medoxomil: Influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens Suppl 2001; 19: S33-40.
18. De B, Bandyopadhyay K, Das T et al. Portal pressure response to losartan compared with propranolol in patients with cirrhosis. Am J Gastroenterol 2003; 98: 1371-6.
19. Henriksen JH, Fuglsang S, Bendtsen F, Moller S. Arterial hypertension in cirrhosis: Arterial compliance, volume distribution, and central haemodynamics. Gut 2006; 55: 380-7.